Danish Breast Cancer Cooperative Group The SKAGEN Trial 1 Moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost: DBCG HYPO II, a randomised clinically controlled trial Number 1-10-72-409-14 Ethical Committee ClinicalTrials.gov Identifier: NCT02384733 1 Version 1.0 01/02/2015 Protocol organisation DBCG-sekretariatet Strandboulevarden 49 2100 København Ø Denmark Tlf.: +45 35 38 65 30 Fax: +45 35 26 35 25 E-mail:
[email protected] Principal Investigator: Consultant, ass. prof., ph.d. Birgitte Vrou Offersen, Department of Oncology, Aarhus University Hospital, Noerrebrogade 44, DK-8000 Aarhus C, Denmark E-mail:
[email protected] 2 Version 1.0 01/02/2015 Participating departments Dept. Oncology Investigator Aalborg Universitetshospital – Consultant Lars Stenbygaard Afsnit Syd
[email protected] Hobrovej 99 9100 Aalborg Dept . Oncology Investigator Aarhus University Hospital Staff specialist Hanne Melgaard Nielsen Noerrebrogade 44,
[email protected] 8000 Aarhus Dept. Oncology Investigator Vejle Sygehus Consultant Erik Hugger Jakobsen Kabbeltoft 25
[email protected] 7100 Vejle Dept. Oncology Investigator Odense University Hospital Consultant Mette Holck Nielsen Sdr. Boulevard 29
[email protected] 5000 Odense C Technische Universität Investigator Dresden Consultant Mechthild Krause Klinik und Poliklinik für Mechthild.Krause@uniklinikum- Strahlentherapie und dresden.de Radioonkologie Universitätsklinikum Dresden Fetscherstrasse 74, 01307 Dresden Germany Praxis für Strahlentherapie Investigator Friedrichstrasse 41 Consultant Andreas Schreiber 01067 Dresden
[email protected] Germany Dept Oncology Investigator Stavanger Consultant Ingvil Mjaaland Norway
[email protected] Dept. Oncology Investigator Herlev Ringvej 75 Consultant Susanne Vallentin 2730 Herlev
[email protected] Rigshospitalet Investigator Dept.